This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Plasma Fractionation Market

Plasma Fractionation Market

Rising Prevalence of Infectious and Chronic Diseases to Stimulate the Plasma Fractionation Market Growth during 2021-2031

Plasma Fractionation Market
FACT4806MR
  • Aug-2021
  • List of Tables : 37
  • List of Figures : 77
  • 170 Pages
  • Healthcare

Market Snapshot

According to Fact.MR, the market for plasma fractionation is anticipated to surpass a CAGR of 7% through 2031, expected to surpass a value of US$ 38 Bn by the end of the forecast period.

The growing demand is due to the increase in respiratory problems faced by various age group of people especially the geriatric population. This, in turn, has increased the need for plasma collection centres. In addition, use of plasma derived immunoglobulins to treat inflammatory diseases has affected the market positively. 

Key Points Covered in Plasma Fractionation Industry Survey

  • Market estimates and forecast 2016-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Plasma Fractionation Market and How to Navigate
  • Recommendation on Key Winning Strategies

Know More Details About the Report

Plasma Fractionation Revenue Analysis 2016-2020 Vs Future Forecast 2021-2031

As per Fact.MR - a market research and intelligence provider, the plasma fractionation market was valued at US$ 19 Bn in 2020, experiencing a historical CAGR worth 5% from 2016-2020.

Plasma derived immunoglobulins are being increasingly used in multiple clinical indications such as autoimmune and inflammatory diseases. The plasma fractionation market has heavily invested in therapies such as Ceruloplasmin, IgA and Plasmin.

In addition, burgeoning investments in innovation and technological advancements in efficient and cost-effective procedures for fractioning proteins shall provide impetus to the market.

On the back of the aforementioned trends, the global plasma fractionation market is poised to experience an uptick in the forecast period (2021-2031). Anticipated CAGR for the market is pegged at a staggering 7%.

How are Increasing Incidences of Infectious Diseases Spurring Adoption?

Life threatening ailments that are a result of stress, infections, congenital deficiencies, trauma and immunological disorders have shown a massive upsurge.  This had led to plasma being majorly used in therapeutic areas in treating patients.

The birth of the novel coronavirus has increased respiratory diseases that directly infects the lungs. Certain patients face difficult due to high blood pressure and diabetes, along with this, family history plays a major role. Thus, to control the ailment, plasma fractionation is applied vastly.

Avail customized purchase options for your needs

How are Technological Advancements Anticipated to Fuel Expansion Prospects?

Advancement in technology has made detection of ailments easier. In addition, awareness of regular check-ups, follow up check-ups has pushed the growth of plasma fractionation.

Key players are investing in various therapies that will produce reliable results. Manufactures are focusing on therapies such as IgA, Plasmin and Ceruloplasmin. This, in turn, is has affected the market for plasma fractionation positively.

Country-wise Analysis

How is the Plasma Fractionation Industry Performing in the U.S?

The U.S market for plasma fractionation shall lay suzerainty during the forecast period, set to capture nearly 2/5th of the market revenue, expanding at a CAGR of 6.6%.

A robust healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in North America. Moreover, the prevalence of neurological and autoimmune diseases as well as haemophilia shall boost demand prospects for plasma fractionation.

What is Uplifting the growth of Plasma Fractionation in the Asian Market?

Asia shows a promising outlook for the growth of the plasma fractionation industry. Therapeutic applicability of plasma fractionation proteins is an important growth lever for the Asia-Pacific market.

Moreover, technological improvements in healthcare sectors of emerging economies are anticipated to pave way for exciting market prospects during the forecast period. Projected CAGR for the Asian market is pegged at a staggering 8%. Also, prevalence of immune and bleeding disorders have prompted investments in plasma fractionation techniques.

An Adaptive Approach to Modern-day Research Needs

Category-wise Insights

Why are Plasma Fractionation Therapies Increasing in the Neurological Domain?

The neurology segment is anticipated to enjoy the lion’s share of the plasma fractionation market. A spurt in neurological disorders is responsible for the growing scope of the neurology segment.

Fact.MR projects that neurological disorders plague more than 450 million people globally. The neurology segment shall account for more than 2/5th of the plasma fractionation market, growing at a CAGR of 7.2%.

What Expansion Prospects Lie Across the Immunology Segment?

Trailing behind is the immunology segment, expanding 1.5x during the forecast period. Rising popularity of immunoglobulins as an important treatment option for autoimmune and inflammatory diseases is anticipated to be a key growth driver.

The immunology segment is anticipated to capture almost one-third of the plasma fractionation market, surpassing a value of US$ 10 Bn by 2031.

Competitive Landscape

The plasma fractionation market consists of multiple players. Innovative product offerings and new product development are key growth strategies adopted by market players.

  • CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.
  • Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.

Have a report related query? Speak to us directly

Report Scope

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value & ‘000 Units for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • GCC
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Key Companies Profiled

  • CSL Behring, Shire Plc.
  • Sanquin
  • Biotest AG
  • GRIFOLS SA
  • Baxter International Inc.
  • Kedrion
  • Octapharma USA Inc.

Pricing

Available upon Request

Key Segments Covered

  • Product

    • Immunoglobulins for Plasma Fractionation
      • Intravenous Immunoglobulins
      • Subcutaneous Immunoglobulins
    • Coagulation Factor Concentrates for Plasma Fractionation
      • Factor VIII
      • Factor IXF
      • Factor XIII
      • Prothrombin Complex Concentrate
      • Von Willebrand Factor (VWF)
      • Fibrinogen Concentrates
    • Albumin for Plasma Fractionation
    • Protease Inhibitors for Plasma Fractionation
    • Other Plasma Products for Plasma Fractionation
  • Application

    • Plasma Fractionation for Neurology
    • Plasma Fractionation for Immunology
    • Plasma Fractionation for Haematology
    • Plasma Fractionation for Critical Care
    • Plasma Fractionation for Pulmonary Applications
    • Plasma Fractionation for Other Applications
  • End User

    • Plasma Fractionation for Hospitals & Clinics
    • Plasma Fractionation for Clinical Research Laboratories
    • Plasma Fractionation for Academic Institutions

Plasma Fractionation Market- Scope of Report

A recent study by Fact.MR on the plasma fractionation market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering plasma fractionation.

The study also provides the dynamics responsible for influencing the future status of the plasma fractionation market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the plasma fractionation market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of plasma fractionation across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of plasma fractionation during the forecast period. Price point comparison by region with global average price is also considered in the study.

Key Questions Answered in Report

  • Which are the most lucrative plasma fractionation markets?
  • Which factors will impact the growth of plasma fractionation?
  • How will changing trends impact the strategies of market players?
  • How can market players capture the low-hanging opportunities across regions?
  • Which companies are leading the plasma fractionation industry?
  • What are the winning strategies of stakeholders in the market?

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Estimates at global and regional levels for plasma fractionation are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global plasma fractionation market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the plasma fractionation market during the forecast period.

Country-specific valuation on demand for plasma fractionation has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition Analysis

The report sheds light on leading manufacturers of plasma fractionation, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering plasma fractionation has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the plasma fractionation domain. 

Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the plasma fractionation industry, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

- FAQs -

According to Fact.MR, sales of plasma fractionation therapeutic solutions are projected to surpass a CAGR of 7%

As of 2020, the plasma fractionation industry was valued at US$ 19 Bn

From 2016 to 2020, plasma fractionation demand expanded at around 5% CAGR

The U.S is expected to account for 40% of overall sales of plasma fractionation during the projected forecast period

Demand for plasma fractionation in Asia is likely to expand at a CAGR of 8% through 2031

Plasma fractionation for treating neurological disorders is anticipated to rise, expanding at a CAGR of 7.2%

Technological advancements in fractionation techniques along with and regular check-ups to detect possible neurological conditions will impact the growth of plasma fractionation

Companies such as CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc are leading the plasma fractionation.

The neurology segment is expected to account for more than two-fifths of the plasma fractionation market.

The immunology segment is likely to be valued at US$ 10 Bn in the forecast period.

Need an Exclusive Report for your Unique Requirement?

Talk Show:

The Rise of Intelligent Packaging

Personalized, Connected and Sustainable

November 18, 2021 11:00-11:45 AM PST (USA & Canada)
This is a LIVE session
Future Market Insights MarketNgage Spring

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.